Rifabutin

Mycobacterium avium complex infection, prophylaxis of Mycobacterium avium complex infection, Tuberculosis + 3 more
Treatment
3 FDA approvals
20 Active Studies for Rifabutin

What is Rifabutin

RifabutinThe Generic name of this drug
Treatment SummaryA broad-spectrum antibiotic used to prevent the spread of Mycobacterium avium complex infection in people with HIV.
Mycobutinis the brand name
image of different drug pills on a surface
Rifabutin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mycobutin
Rifabutin
1992
10

Approved as Treatment by the FDA

Rifabutin, also known as Mycobutin, is approved by the FDA for 3 uses like Mycobacterium avium complex infection and prophylaxis of Mycobacterium avium complex infection .
Mycobacterium avium complex infection
prophylaxis of Mycobacterium avium complex infection
HIV

Effectiveness

How Rifabutin Affects PatientsRifabutin is an antibiotic used to fight bacteria. It works by stopping bacteria from making proteins needed for their survival. It kills both gram-positive and gram-negative bacteria and is especially effective against Mycobacterium tuberculosis. However, it is only used for a few specific infections because bacteria can quickly become resistant to it. When taken orally, rifabutin is easily absorbed and spread throughout the body, including in the brain. It is broken down in the liver and removed from the body through bile and urine. It does not need to be adjusted for people with kidney problems.
How Rifabutin works in the bodyRifabutin works by stopping bacteria from making new RNA, which in turn leads to the death of the bacteria.

When to interrupt dosage

The advised dosage of Rifabutin is dependent upon the perceived situation, such as HIV, Stomach Ulcer and Tuberculosis (TB). The degree of dosage shifts, in agreement with the method of delivery (e.g. Capsule - Oral or Capsule, delayed release) indicated in the table beneath.
Condition
Dosage
Administration
Helicobacter Pylori Infection
150.0 mg, , 12.5 mg
, Oral, Capsule, Capsule - Oral, Capsule, delayed release - Oral, Capsule, delayed release
Mycobacterium avium complex infection
150.0 mg, , 12.5 mg
, Oral, Capsule, Capsule - Oral, Capsule, delayed release - Oral, Capsule, delayed release
prophylaxis of Mycobacterium avium complex infection
150.0 mg, , 12.5 mg
, Oral, Capsule, Capsule - Oral, Capsule, delayed release - Oral, Capsule, delayed release
Tuberculosis
150.0 mg, , 12.5 mg
, Oral, Capsule, Capsule - Oral, Capsule, delayed release - Oral, Capsule, delayed release
HIV
150.0 mg, , 12.5 mg
, Oral, Capsule, Capsule - Oral, Capsule, delayed release - Oral, Capsule, delayed release
Tuberculosis
150.0 mg, , 12.5 mg
, Oral, Capsule, Capsule - Oral, Capsule, delayed release - Oral, Capsule, delayed release

Warnings

Rifabutin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Rifabutin.
Common Rifabutin Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Rifabutin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Rifabutin.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Rifabutin.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Rifabutin.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Rifabutin.
Rifabutin Toxicity & Overdose RiskThe toxic dose of this drug in male mice has been found to be 4.8 g/kg.
image of a doctor in a lab doing drug, clinical research

Rifabutin Novel Uses: Which Conditions Have a Clinical Trial Featuring Rifabutin?

127 active clinical trials are being conducted to investigate the potential of Rifabutin to provide prophylaxis against Mycobacterium avium complex infection, Stomach Ulcer and Tuberculosis (TB).
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Tuberculosis
0 Actively Recruiting
prophylaxis of Mycobacterium avium complex infection
0 Actively Recruiting
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Tuberculosis
2 Actively Recruiting
Phase 3, Phase 2
Mycobacterium avium complex infection
1 Actively Recruiting
Phase 2

Rifabutin Reviews: What are patients saying about Rifabutin?

1Patient Review
10/6/2014
Rifabutin for Mycobacterium Avium Bacteria Infection
I'm only two weeks in on this medication, and I can't take it anymore. The side effects are unbearable.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rifabutin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is another name for rifabutin?

"Rifabutin can help to prevent Mycobacterium avium complex, which is a serious bacterial infection that mostly affects people who have HIV."

Answered by AI

What kind of antibiotic is rifabutin?

"Rifabutin is a medication used to treat infections caused by bacteria. It works by killing the bacteria that cause infection. Rifabutin will not work for colds, flu, or other viral infections."

Answered by AI

What are side effects of rifabutin?

"Burning, dry or red eyes, watery diarrhea, severe pain or tenderness in stomach, and itching or discharge in eyes are all symptoms of pink eye."

Answered by AI

What is rifabutin used for?

"Rifabutin is a medication used to help prevent MAC disease caused by Mycobacterium avium or Mycobacterium intracellulare bacteria from affecting the body in patients with advanced HIV infection."

Answered by AI

Clinical Trials for Rifabutin

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Rifabutin clinical trials? We made a collection of clinical trials featuring Rifabutin, we think they might fit your search criteria.Go to Trials
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA
The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.
Waitlist Available
Has No Placebo
Center on Substance Use and HealthGlenn-Milo Santos, PhD, MPH
Have you considered Rifabutin clinical trials? We made a collection of clinical trials featuring Rifabutin, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Rifabutin clinical trials? We made a collection of clinical trials featuring Rifabutin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security